Cantor Fitzgerald Sticks to Its Buy Rating for Optinose Inc (OPTN)

In a report released today, Brandon Folkes from Cantor Fitzgerald maintained a Buy rating on Optinose Inc (OPTN), with a price target of $27. The company’s shares closed yesterday at $10.79.

Folkes noted:

“. Post 1Q19, we are reiterating our OW rating and $27 12- month PT for OPTN. Despite a lumpy Xhance initial launch, we believe we are beginning to see Xhance gain traction, which supports our confidence in the peak sales potential of the product. In 2019, we believe the increased access, better affordability, the sales force expansion and increased awareness of the good efficacy data should continue to drive script growth throughout the year, and beyond. OPTN has evolved aspects of its launch strategy, which we view as positive and believe are beginning to pay dividends. We continue to take a conservative approach to Xhance revenue in 2019 while the updated launch strategy is fully implemented.”

According to, Folkes is a 1-star analyst with an average return of -1.9% and a 33.7% success rate. Folkes covers the Healthcare sector, focusing on stocks such as Opiant Pharmaceuticals Inc, Eagle Pharmaceuticals Inc, and Collegium Pharmaceutical.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Optinose Inc with a $25.50 average price target.

See today’s analyst top recommended stocks >>

Based on Optinose Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $26.38 million. In comparison, last year the company had a GAAP net loss of $30.57 million.

Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

OptiNose, Inc. is a pharmaceutical company, which engages in the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. Its products include the XHANCE and ONZETRA Xsail. The company was founded by Per Gisle Djupesland and Helena Kyttari Djupesland in May 2010 and is headquartered in Yardley, PA.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts